Osteoarthritis drug developer Paradigm says its purchase of an oral drug candidate won't distract it from its key phase III .

Kalshi, a prediction market platform, has raised a $185 million investment round, pushing its valuation to $2 billion.

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

Kalshi raises $185M at $2B valuation, signaling prediction market maturity and crypto sector growth amid regulatory challenges.

GTE raised $15M in Series A funding led by Paradigm, aiming to become the fastest decentralized exchange and rival major ...

Kalshi achieved unicorn status following its latest Series C funding round, amid the prediction markets platform's growing ...

A new DEX called GTE has received funding support to beat the existing CEXs and DEXs using its CLOB model. Can it overcome ...

In February 2025, BioRestorative Therapies announced that the FDA cleared its Investigational New Drug (IND) application for ...